Cargando…

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018

BACKGROUND: Mecillinam is a unique amidinopenicillin antibiotic, being the first and the only compound in its class. In contrast to other beta-lactams, it has a unique mechanism of action whereby it exerts its antibacterial activity through binding to penicillin binding protein 2. Pivmecillinam is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawser, Stephen, Morrissey, Ian, Charrier, Cedric, De Piano, Cyntia, Alexander, Morton, Henriksen, Anne Santerre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778237/ http://dx.doi.org/10.1093/ofid/ofaa439.1797

Ejemplares similares

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019
por: Hawser, Stephen, et al.
Publicado: (2021)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam
por: Fuchs, Frieder, et al.
Publicado: (2021)

In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales
por: Plambeck, Lars, et al.
Publicado: (2022)

Reviving the role of mecillinam against extended spectrum beta-lactamase producing enterobacterales
por: Kaleem, Fatima, et al.
Publicado: (2022)

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales
por: Lodise, Thomas P, et al.
Publicado: (2021)

Retracted: In vivo mecillinam resistance in Escherichia coli after pivmecillinam treatment of a urinary tract infection
Publicado: (2019)

Mecillinam – Reversion of Resistance and How to Test It
por: Frimodt-Moller, Niels
Publicado: (2017)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021
por: Belley, Adam, et al.
Publicado: (2023)

The surgions mate, 1617
Publicado: (1979)

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France
por: Farfour, Eric, et al.
Publicado: (2022)

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
por: Henriksen, Anne Santerre, et al.
Publicado: (2021)

High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli
por: Søraas, Arne, et al.
Publicado: (2014)

1293. In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
por: Hackel, Meredith, et al.
Publicado: (2021)

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20
por: Karlowsky, James A, et al.
Publicado: (2023)

1617. Mumps in Detention Facilities that House Detained Migrants—United States, September 2018–April 2019
por: Leung, Jessica, et al.
Publicado: (2019)

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)

Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review
por: Jansåker, Filip, et al.
Publicado: (2018)

Carbapenemase production among less-common Enterobacterales genera: 10 US sites, 2018
por: Shugart, Alicia, et al.
Publicado: (2021)

1617. Assessment of Bloodstream Infections in Patients with Intrapartum Fever
por: Kamel, Barbara, et al.
Publicado: (2023)

Multidrug-Resistant Enterobacterales in Community-Acquired Urinary Tract Infections in Djibouti, Republic of Djibouti
por: Mohamed, Hasna Said, et al.
Publicado: (2022)

704. Incidence and Patient Outcomes of S. aureus Isolates from Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with High Iclaprim MIC values in Phase 3 REVIVE Trials
por: Huang, David B, et al.
Publicado: (2019)

Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales
por: Zalacain, Magdalena, et al.
Publicado: (2021)

Ibuprofen versus mecillinam for uncomplicated cystitis - a randomized controlled trial study protocol
por: Vik, Ingvild, et al.
Publicado: (2014)

Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine
por: Thulin, Elisabeth, et al.
Publicado: (2017)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

Analysis of Susceptibilities of Carbapenem Resistant Enterobacterales to Colistin in Intra-Abdominal, Respiratory and Urinary Tract Infections from 2015 to 2017
por: Zhang, Hui, et al.
Publicado: (2020)

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)
por: Sader, Helio S., et al.
Publicado: (2023)

Treatment duration of complicated urinary tract infections by extended-spectrum beta-lactamases producing enterobacterales
por: Álvarez Otero, Judith, et al.
Publicado: (2020)

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
por: Dunne, Michael W., et al.
Publicado: (2022)

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales
por: Bouiller, Kévin, et al.
Publicado: (2022)

Risk Factors for Community-Acquired Urinary Tract Infections Caused by Multidrug-Resistant Enterobacterales in Thailand
por: Assawatheptawee, Kanit, et al.
Publicado: (2022)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

The Worshipful Society of Apothecaries of London: A History, 1617–1967
por: Trail, R. R.
Publicado: (1969)

2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_crdt4b513al4tu4mr69ijvet96